about
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.STAMP alters the growth of transformed and ovarian cancer cells.Interfering with mineralocorticoid receptor activation: the past, present, and futureMineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL).11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature.Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized Dahl salt-sensitive rats.Psychobiology of depression/distress in congestive heart failureOxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosteroneExamination of the potential association of stress with morbidity and mortality outcomes in patient with heart failure.Aldosterone: good guy or bad guy in cerebrovascular disease?Pharmacological management of renal fibrotic disease.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Why are mineralocorticoid receptor antagonists cardioprotective?Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension.11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemiaPotential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor.Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure.Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade.The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia.Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials.Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis.Are macrophages the foot soldiers in the war waged by aldosterone against the heart?Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction.Clinical Characteristics of Aldosterone- and Cortisol-Coproducing Adrenal Adenoma in Primary Aldosteronism.
P2860
Q24604026-05C922E5-4A97-48D1-9CA1-8834FEF52C23Q33550597-8402B1B4-41FE-4F36-8BF4-FC88EB25A273Q34019947-6E85C968-3EA0-4B27-9939-F818B8EFD32BQ34121798-4286BF3E-2945-4482-882B-2C0807E379C9Q34403980-271DA9EB-C824-4E80-8FEB-B3E0E9A09825Q34483976-75F03FAE-A7F7-4B7D-8054-5D469E4D29CEQ34726918-4AD3AFFA-E78B-45EA-9C26-3DF33338D829Q35135088-6336E912-8C92-4A75-BF31-235C5E28C6DBQ35135164-7D019E3C-4FCE-4CFE-A0AA-F1F9FB60E9A1Q35293910-E29002F9-2DF0-48CA-A095-5803D554D6ACQ35461760-83C9540A-A2ED-490A-AFF4-55DFB035497AQ35911866-5EB132B4-F87F-4CF4-8EE7-4DFB7B09A5BCQ36280944-7EA6D006-C4C8-4E1C-A93E-AFF8D7C6E5FCQ36407348-126D8102-CB8C-4195-A158-FEBC388B9950Q36437145-E21766EE-DD71-42A2-B241-2CB7C74D3B3DQ36639935-2FDC808F-CB3D-45A2-9A93-BC617A6603DBQ36883558-7260D23E-2351-469F-A843-1E67E244012FQ37106695-816DF0B0-E2D6-4FE6-B35E-5C3F269F748CQ37196407-0AB9FD26-E87D-4B5D-86D8-AE4750157BD8Q37889518-4C27DFF1-0AC7-4AA9-8C0A-0D91CC8CDC21Q37945452-F3CFEB81-A50E-47D6-B8F7-6C01DCF80EB2Q38072297-A30E0642-7B48-411D-AE98-17120701D199Q38658657-E8806079-D093-4EAA-8EEF-300651AEF146Q39199991-3C670E2B-5B36-4F71-93CF-9A3754228BDDQ39416346-368ABEC1-7B70-4D5E-B403-74F23422F05BQ40292966-294D82D3-2008-41DD-A487-3A3AFBA7FA72Q41064263-6E7A67BA-D9E5-489C-A73E-216B9506AA12Q41875563-2906D266-598E-4FE9-B9D4-1455E91FFEF9Q41889468-DF788523-1F06-4670-91F3-5C0E2FE23823Q42699382-74382FEB-B960-43C4-A111-862C0457AA83Q46060609-C6A32B65-5A5B-4AEB-AE75-73B5E3EAA093Q55096183-478CEADB-990D-4935-9F7B-D305C4BA5EB5
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
RALES, EPHESUS and redox.
@en
RALES, EPHESUS and redox.
@nl
type
label
RALES, EPHESUS and redox.
@en
RALES, EPHESUS and redox.
@nl
prefLabel
RALES, EPHESUS and redox.
@en
RALES, EPHESUS and redox.
@nl
P1476
RALES, EPHESUS and redox.
@en
P2093
John W Funder
P304
P356
10.1016/J.JSBMB.2004.12.010
P577
2005-01-28T00:00:00Z